ScreenerHero

VXRT Vaxart, Inc.

NAS · US · Healthcare · Biotechnology · vaxart.com
0.4306USD-11.40%Mkt Cap: 118.19M $P/E: 2.86

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap118.19M USD
Enterprise Value54.50M USD
Revenue (TTM)243.06M USD
Gross Profit58.80M USD
Net Income (TTM)16.33M USD
Revenue/Share1.03 USD
Last Price0.4306 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.86
P/E (Forward)-0.43
PEG—
EV/EBITDA1.20
EV/Revenue0.22
P/S0.44
P/B1.13
EPS (TTM)0.18
EPS (Forward)-1.03
52W Range
0.310023% of range0.8400
52W High0.8400 USD
52W Low0.3100 USD
Profitability
Gross Margin24.19%
Oper. Margin-48.45%
EBITDA Margin18.77%
Profit Margin6.88%
ROE18.60%
ROA8.77%
Growth
Revenue Growth-31.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF7.71M USD
CapEx (TTM)145.00K USD
FCF Margin-7.06%
FCF Yield-14.51%
Net Debt-51.44M USD
Net Debt/EBITDA-1.13
Balance Sheet
Debt/Equity0.10
Current Ratio1.60
Quick Ratio1.52
Book Value/Sh0.39 USD
Cash/Share0.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateNov 9, 2012
Pay DateFeb 14, 2018
Splits
Last Split1:11
Split DateFeb 14, 2018
Analyst Consensus
Rating—
Target (Mean)3.333 USD
Upside (mean)+674.1%
Target Range2.000 USD – 4.000 USD
2.000+674.1% to mean4.000
# Analysts3
Ownership
Shares Out.243.70M
Float239.25M
Insiders1.42%
Institutions0.05%
Short Interest
Short Ratio1.9d
Short % Float7.51%
Short % Out.7.41%
Shares Short16.96M
Short (prev mo.)14.68M
Technical
SMA 500.5018 (-14.2%)
SMA 2000.5870 (-26.7%)
Beta1.06
S&P 52W Chg16.45%
Avg Vol (30d)117.84K
Avg Vol (10d)260.52K
Technical Indicators
RSI (14)44.1
MACD-0.0141
MACD Signal-0.0128
MACD Hist.-0.0013
BB Upper0.5582 USD
BB Middle0.5048 USD
BB Lower0.4514 USD
BB Width21.17%
ATR (14)0.0369 USD
Vol Ratio (20d)0.29x